NASDAQ / LIVE COMPANY INTELLIGENCE

Generate Biomedicines, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERGENB
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / GENB COVERAGE

What’s moving Generate Biomedicines, Inc. now

Current reporting with the operating signal separated from the noise.

01
Zacks Investment Research

Generate Biomedicines, Inc. (GENB) Return On Assets (TTM)

The story matters when it changes Generate Biomedicines, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Generate Biomedicines, Inc. (GENB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Generate Biomedicines, Inc. (GENB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

The story matters when it changes Generate Biomedicines, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

The story matters when it changes Generate Biomedicines, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering

Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering

The story matters when it changes Generate Biomedicines, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest GENB filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-07 · Period 2026-03-31SEC ↗8-KMaterial company eventFiled 2026-05-07 · Period 2026-05-07SEC ↗8-KMaterial company eventFiled 2026-03-02 · Period 2026-02-26SEC ↗SCHEDULE 13GOfficial SEC filingFiled 2026-05-15SEC ↗SCHEDULE 13GOfficial SEC filingFiled 2026-05-15SEC ↗3Official SEC filingFiled 2026-03-12 · Period 2026-03-02SEC ↗4Official SEC filingFiled 2026-03-06 · Period 2026-03-04SEC ↗4Official SEC filingFiled 2026-03-02 · Period 2026-02-26SEC ↗
EARNINGS / QUARTERLY TRACKER

Generate Biomedicines, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.